ALK-Abello sees 2026 revenue ex-FX +11% to +15%

ALK-Abello sees 2026 revenue ex-FX +11% to +15%

ALK-Abelló Upgrades 2025 Financial Outlook Amid Strong Business Momentum

ALK-Abelló A/S (ALKB:DC / OMX: ALK B), a global specialty pharmaceutical company focused on allergy and allergic asthma treatments, has revised its full-year 2025 financial outlook following robust third-quarter performance and a positive near-term outlook. The company now anticipates revenue growth of 13-15% in local currencies for 2025, up from its prior guidance of 12-14%. This adjustment reflects increased demand for its allergy immunotherapy (AIT) and anaphylaxis products, driven by higher patient volumes across all sales regions.

The EBIT margin is projected to rise to approximately 26% in 2025, exceeding the previous estimate of 25%, as revenue growth combines with gross margin improvements and operational optimizations. ALK attributed the stronger performance to sustained business momentum in Europe, a key market for the company.

The third-quarter report, originally scheduled for 13 November 2025, was released early on 12 November 2025, with an investor and analyst presentation held as planned the following day at 13:30 CET. Following the upgraded outlook, ALK-Abelló’s shares surged 11% in early trading, reflecting investor confidence in the company’s trajectory.

ALK-Abelló, headquartered in Hørsholm, Denmark, employs approximately 2,800 people globally and markets allergy immunotherapy treatments for patients and diagnostic tools for healthcare professionals. The company emphasized that the updated guidance aligns with its long-term strategic priorities and operational focus.

For further details, investors may contact ALK’s investor relations team at +45 4574 7527 or review the full Q3 report.

This announcement complies with EU Market Abuse Regulation requirements for insider information disclosure.

(https://ir.alk.net/news-releases/news-release-details/alk-upgrades-its-full-year-outlook): ALK-Abelló’s 12 November 2025 news release.
(https://ir.alk.net/news-releases/news-release-details/alk-upgrades-its-full-year-outlook): ALK-Abelló’s investor relations website.
(https://www.investing.com/news/earnings/alkabello-raises-2025-outlook-after-strong-q3-shares-jump-11-93CH-4354472): Investing.com, 12 November 2025.